Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Pediatrics & Neonatal Care Volume 5 (2019), Article ID 5:IJPNC-152, 6 pages
https://doi.org/10.15344/2455-2364/2019/152
Case Study
Assessment of Risk Factors, which Affect the Presence of Inhibitors in Children with Hemophilia A: The Albanian Case-control Study

Arlind Deveja1, Donjeta Bali2, Mirela Xhafa2, Mirzana Kapllanaj2, Etleva Refatllari3 and Anila Godo4,*

1Department of Pediatrics, University Hospital Center ‘Mother Teresa’ Tirana, Albania
2Pediatric Hematologist/Oncologist, University Hospital Center ‘Mother Teresa’ Tirana, Albania
3Laboratory of Clinical Chemistry and Hematology, University Hospital Center ‘Mother Teresa’ Tirana, Albania
4Pediatric Hematologist/Oncologist, Chief of Department of Pediatrics, University Hospital Center ‘Mother Teresa’ Tirana
Dr. Anila Godo, Pediatric Hematologist/Oncologist, Chief of Department of Pediatrics, University Hospital Center ‘Mother Teresa’ Tirana, Albania; E-mail: godoanila@gmail.com
07 February 2019; 23 April 2019; 25 April 2019
Deveja A, Bali D, Xhafa M, Kapllanaj M, Refatllari E, et al. (2019) Assessment of Risk Factors, which Affect the Presence of Inhibitors in Children with Hemophilia A: The Albanian Case-control Study. Int J Pediatr Neonat Care 5: 152. doi: https://doi.org/10.15344/2455-2364/2019/152
© 2019 Deveja et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Astermark J, Berntorp E, White G, Kroner B (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia 7: 267-272. [CrossRef] [Google Scholar] [PubMed]
  2. Franchini M, Mannucci P (2012) Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 7: 24. [CrossRef] [Google Scholar] [PubMed]
  3. Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M et al. (2013) Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 121: 4046-4055. [CrossRef] [Google Scholar] [PubMed]
  4. Gouw S, Van Den Berg H, Le Cessie S, Van Der Bom J (2005) Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 5: 1383-1390. [CrossRef] [Google Scholar] [PubMed]
  5. Gouw S, van der Bom J, Marijke van den Berg H (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109: 4648-4654. [CrossRef] [Google Scholar] [PubMed]
  6. Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, et al. (1997) HLA Class II Profile: A Weak Determinant of Factor VIII Inhibitor Development in Severe Haemophilia A. Thromb Haemost 77: 234-237. [CrossRef] [Google Scholar] [PubMed]
  7. Kosaka N, Izumi H, Sekine K, Ochiya T (2010) microRNA as a new immuneregulatory agent in breast milk. Silence 1: 7. [CrossRef] [Google Scholar] [PubMed]
  8. Leissinger C, Cooper D, Solem C (2011) Assessing the impact of age, race, ethnicity and inhibitor status on functional limitations of patients with severe and moderately severe haemophilia A. Haemophilia 17: 884-889. [CrossRef] [Google Scholar] [PubMed]
  9. Mauser-Bunschoten E, Fischer K, van den Berg M, van der Bom J (2003) Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 89: 475-479. [Google Scholar] [PubMed]
  10. Meeks S, Batsuli G (2016) Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology 2016: 657-662. [CrossRef] [Google Scholar] [PubMed]
  11. Miller C (2018) Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review. Haemophilia 24: 186-197. [CrossRef] [Google Scholar] [PubMed]
  12. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M et al. (1995) Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation. Thromb Haemost 74: 1402-1406. [Google Scholar] [PubMed]
  13. Wight J, Paisley S (2003) The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 9: 418-435. [CrossRef] [Google Scholar] [PubMed]
  14. Witmer C, Young G (2012) Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 4: 59-72. [CrossRef] [Google Scholar] [PubMed]
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.